Our mission is to develop a radically new approach for the treatment of severe, chronic autoimmune diseases.
- Appointment of new Scientific Advisory Board comprising thought leaders from academia and industry to boost pipeline progress and expansion
- New laboratories will accommodate growing team and increased activities
- Move supported by key shareholder Noshaq and SPI and confirms Imcyse’s commitment to the Walloon Region of Belgium, a leading center for talent and R&D within Europe
More Articles ...
- INNODIA is ready for a new phase - clinical trials
- Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder
- Imcyse Enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in Rheumatoid Arthritis
- Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes
- The beginning of the end for Type I diabetes: A new view from immunotherapy science
- Imcyse Announces the Appointment of Denis Bedoret as Chief Executive Officer
- Imcyse Awarded Subsidy from the Walloon Region for Neuromyelitis Optica Spectrum Disorder Study
- Imcyse Joins Type 1 Diabetes IMI Consortium INNODIA
- Imcyse to present late-breaking abstract of its Imotope-based antigen-specific immunotherapy for autoimmune diseases at ASIT 2020
- Imcyse to present first-in-human phase 1B study results in Type 1 diabetes at EASD 2019
- Imcyse to present positive results in EAE model of multiple sclerosis at ECTRIMS 2019
- Imcyse reports successful first-in-human phase 1B study in type 1 diabetes with IMCY-0098
- Imcyse announces changes in management and board, appoints Thomas Taapken as Executive Chairman
- Imcyse secures total of €35M in Series B financing round and additional grants
Page 1 of 4
Address
Headquarters:
Avenue Pré-Aily 14
4031 Liège (Angleur)
BELGIUM
Phone : +32 (0)4 325 1100
 |
 |
|
© Imcyse 2022 - All rights reserved |
|